|
93107 | Becks has been trying to diversify for a while now. Five years ago in some regions lineup was >2/3 Pioneer. Pioneer started raising fees and Becks went to St Louis, signed a deal to have more rights to use germplasm rather than just selling hybrid/variety.
As for the Tech fees, Corteva has a commitment to Wall Street to start showing some profits from outlicensing traits. They seem slow to convert to E3, given that Dow/Mycogen has been working on Enlist for over 10 years.
| |
|
Corteva and Becks
